Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mevalotin Retains Top Ranking Despite GE Competition
July 19, 2004
- Eli Lilly Japan Aims at 20th Place by 2010: Mr Crenshaw
July 12, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 12, 2004
- Siebel Confident on Domestic Prospects for CRM Business
July 12, 2004
- Chugai R&D Focuses on Low-Molecular-Weight Agonist Antibodies
July 12, 2004
- Policy Promotion HQ Sets Up Coordinators' Group
July 12, 2004
- Takeda, AnGes MG, Sato Sports Join "22nd Century Medical Center" Project
July 12, 2004
- REGULATORY NEWS IN BRIEF
July 12, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 12, 2004
- Generics Offer Economic Benefits to Patients, Med Institutions: Utobrain Seminar
July 12, 2004
- PRESS SEMINAR
July 12, 2004
- Taiyo Pharm Conducts Tour of Takayama Plant
July 12, 2004
- Nihon Medi-physics: Benzodine Inj. for Imaging of Epileptic Focus
July 12, 2004
- EPMA Considers Affiliation with IGPA
July 12, 2004
- Use of AED by the General Public Should Be Promoted: JHF Seminar
July 12, 2004
- Number of e-Details with MR-kun Exceeds 1.1 Mil. per Qtr
July 12, 2004
- Council on Ethical Drug Distribution Holds 1st Meeting
July 12, 2004
- Press Seminar
July 12, 2004
- BUSINESS NEWS IN BRIEF
July 12, 2004
- NEW PRODUCTS
July 12, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…